DUSP6 and neuroblastoma: In SH‐SY5Y NB cells, treatment with BCI led to a dose‐dependent decrease in ERK activity and cell viability, hinting that pharmacological inhibition of DUSP1 and DUSP6 could potentially reduce NB cell growth [21].